dc.contributor.author |
Mohammed, Mohammed A |
|
dc.contributor.author |
Moles, Rebekah J |
|
dc.contributor.author |
Hilmer, Sarah N |
|
dc.contributor.author |
Kouladjian O'Donnel, Lisa |
|
dc.contributor.author |
Chen, Timothy F |
|
dc.coverage.spatial |
England |
|
dc.date.accessioned |
2021-12-07T20:37:51Z |
|
dc.date.available |
2021-12-07T20:37:51Z |
|
dc.date.issued |
2018-1-11 |
|
dc.identifier.citation |
BMJ open 8(1):e018880 11 Jan 2018 |
|
dc.identifier.issn |
2044-6055 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/57681 |
|
dc.description.abstract |
<h4>Objective</h4>Medication-related burden (MRB) is a negative experience with medicine, which may impact on psychological, social, physical and financial well-being of an individual. This study describes the development and initial validation of an instrument specifically designed to measure MRB on functioning and well-being-the Medication-Related Burden Quality of Life (MRB-QoL) tool.<h4>Methods</h4>An initial pool of 76-items for MRB-QoL was generated. The link to MRB-QoL survey was sent to a sample of consumers living with at least one chronic medical condition and taking ≥3 prescription medicines on a regular basis. Exploratory factor analysis (EFA) was used to determine the underlining factor structure. Internal consistency (Cronbach's α) and construct validity were examined. The latter was examined through correlation with Medication Regimen Complexity Index (MRCI), Drug Burden Index (DBI) and Charlson's Comorbidity Index (CCI).<h4>Results</h4>367 consumers completed the survey (51.2% male). EFA resulted in a 31-item, five-factor solution explaining 72% of the total variance. The five subscales were labelled as 'Routine and Regimen Complexity' (11 items), 'Psychological Burden' (six items), 'Functional and Role Limitation' (seven items), 'Therapeutic Relationship' (three items) and 'Social Burden' (four items). All subscales showed good internal consistency (Cronbach's α 0.87 to 0.95). Discriminant validity of MRB-QoL was demonstrated via its correlations with MRCI (Spearman's r -0.16 to 0.08), DBI (r 0.12 to 0.28) and CCI (r -0.23 to -0.15). Correlation between DBI and 'Functional and Role Limitation' subscale (r 0.36) indicated some evidence of convergent validity. Patients with polypharmacy, multiple morbidity and DBI >0 had higher median scores of MRB-QoL providing evidence for known group validity.<h4>Conclusions</h4>The MRB-QoL V.1 has good construct validity and internal consistency. The MRB-QoL may be a useful humanistic measure for evaluating the impact of pharmaceutical care interventions on patients' quality of life. Future research is warranted to further examine additional psychometric properties of MRB-QoL V.1 and its utility in patient care. |
|
dc.format.medium |
Electronic |
|
dc.language |
eng |
|
dc.publisher |
BMJ |
|
dc.relation.ispartofseries |
BMJ open |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by-nc/4.0/ |
|
dc.subject |
Humans |
|
dc.subject |
Drug Therapy |
|
dc.subject |
Severity of Illness Index |
|
dc.subject |
Factor Analysis, Statistical |
|
dc.subject |
Reproducibility of Results |
|
dc.subject |
Health Knowledge, Attitudes, Practice |
|
dc.subject |
Psychometrics |
|
dc.subject |
Cost of Illness |
|
dc.subject |
Quality of Life |
|
dc.subject |
Aged |
|
dc.subject |
Middle Aged |
|
dc.subject |
Female |
|
dc.subject |
Male |
|
dc.subject |
Medication Adherence |
|
dc.subject |
general medicine (see internal medicine) |
|
dc.subject |
therapeutics |
|
dc.subject |
Aged |
|
dc.subject |
Cost of Illness |
|
dc.subject |
Drug Therapy |
|
dc.subject |
Factor Analysis, Statistical |
|
dc.subject |
Female |
|
dc.subject |
Health Knowledge, Attitudes, Practice |
|
dc.subject |
Humans |
|
dc.subject |
Male |
|
dc.subject |
Medication Adherence |
|
dc.subject |
Middle Aged |
|
dc.subject |
Psychometrics |
|
dc.subject |
Quality of Life |
|
dc.subject |
Reproducibility of Results |
|
dc.subject |
Severity of Illness Index |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Medicine, General & Internal |
|
dc.subject |
General & Internal Medicine |
|
dc.subject |
OLDER-PEOPLE |
|
dc.subject |
PHARMACEUTICAL CARE |
|
dc.subject |
REGIMEN COMPLEXITY |
|
dc.subject |
PHYSICAL FUNCTION |
|
dc.subject |
ADVERSE OUTCOMES |
|
dc.subject |
CHRONIC ILLNESS |
|
dc.subject |
HEALTH |
|
dc.subject |
INDEX |
|
dc.subject |
POLYPHARMACY |
|
dc.subject |
MULTIMORBIDITY |
|
dc.subject |
1117 Public Health and Health Services |
|
dc.subject |
Clinical |
|
dc.subject |
Behavioral and Social Science |
|
dc.subject |
Clinical Research |
|
dc.subject |
7.1 Individual care needs |
|
dc.subject |
1103 Clinical Sciences |
|
dc.subject |
1117 Public Health and Health Services |
|
dc.subject |
1199 Other Medical and Health Sciences |
|
dc.title |
Development and validation of an instrument for measuring the burden of medicine on functioning and well-being: the Medication-Related Burden Quality of Life (MRB-QoL) tool. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1136/bmjopen-2017-018880 |
|
pubs.issue |
1 |
|
pubs.begin-page |
e018880 |
|
pubs.volume |
8 |
|
dc.date.updated |
2021-11-02T04:19:15Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/29330175 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
research-article |
|
pubs.subtype |
Validation Study |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
785438 |
|
dc.identifier.eissn |
2044-6055 |
|
dc.identifier.pii |
bmjopen-2017-018880 |
|
pubs.number |
ARTN e018880 |
|
pubs.online-publication-date |
2018-1-11 |
|